Estudo randomizado | Efetividade da fosfomicina no tratamento de infecções de trato urinário por Escherichia coli multirresistente.
14 Mar, 2022 | 13:37hComentários:
The Role of Intravenous Fosfomycin: Finding Our Way Out of Dante’s Forest Dark – JAMA Network Open
Fosfomycin Not Noninferior to Comparators for Bacteremic UTI – HealthDay
‘Forgotten’ antibiotic recovered for resistant bacterial infections – University of Seville
Comentário no Twitter
In this RCT, fosfomycin did not demonstrate noninferiority in MDR-E coli bacteremic UTI, mostly due to adverse event-related withdrawals in mITT, but showed efficacy in per protocol analysis. #FORESTtrial @jesusrbano https://t.co/oiPtiQo2XA pic.twitter.com/Q44QQb18cN
— JAMA Network Open (@JAMANetworkOpen) January 13, 2022


